Form 6-K ASTRAZENECA PLC For: Jul 17
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of July 2015
Commission File Number: 001-11960
AstraZeneca PLC
2 Kingdom Street, London W2 6BD
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
|
||||
1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached: ii
|
AstraZeneca PLC
|
|||
2 Reason for the notification (please tick the appropriate box or boxes):
|
||||
An acquisition or disposal of voting rights
|
X | |||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
|
||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
|
||||
An event changing the breakdown of voting rights
|
||||
Other (please specify):
|
||||
3. Full name of person(s) subject to the
notification obligation: iii
|
The Capital Group Companies, Inc.
|
|||
4. Full name of shareholder(s)
(if different from 3.):iv
|
See Schedule A
|
|||
5. Date of the transaction and date on
which the threshold is crossed or
reached: v
|
15 July 2015
|
|||
6. Date on which issuer notified:
|
16 July 2015
|
|||
7. Threshold(s) that is/are crossed or
reached: vi, vii
|
Above 3%
|
8. Notified details:
|
||||||||||||||||
A: Voting rights attached to shares viii, ix
|
||||||||||||||||
Class/type of
shares
if possible using
the ISIN CODE
|
Situation previous
to the triggering
transaction
|
Resulting situation after the triggering transaction
|
||||||||||||||
Number
of
Shares
|
Number
of
Voting
Rights
|
Number
of shares
|
Number of voting
rights
|
% of voting rights x
|
||||||||||||
Direct
|
Direct xi
|
Indirect xii
|
Direct
|
Indirect
|
||||||||||||
Ordinary
(GB0009895292)
|
30,372,883
|
30,372,883
|
30,472,596
|
2.4115%
|
||||||||||||
ADRs
(us0463531089)
|
7,452,630
|
7,452,630
|
7,453,217
|
0.5898%
|
||||||||||||
B: Qualifying Financial Instruments
|
||||||||||||||||
Resulting situation after the triggering transaction
|
||||||||||||||||
Type of financial
instrument
|
Expiration
date xiii
|
Exercise/
Conversion Period xiv
|
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
|
% of voting
rights
|
||||||||||||
n/a
|
||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
|
||||||||||||||||
Resulting situation after the triggering transaction
|
||||||||||||||||
Type of financial
instrument
|
Exercise price
|
Expiration date xvii
|
Exercise/
Conversion period xviii
|
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|||||||||||
n/a
|
Nominal
|
Delta
|
||||||||||||||
Total (A+B+C)
|
||||||||||||||||
Number of voting rights
|
Percentage of voting rights
|
|||||||||||||||
37,925,813
|
3.0013%
|
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi
|
||
See Schedule A
|
||
Proxy Voting:
|
||
10. Name of the proxy holder:
|
||
11. Number of voting rights proxy holder will cease
to hold:
|
||
12. Date on which proxy holder will cease to hold
voting rights:
|
||
13. Additional information:
|
||
14. Contact name:
|
||
15. Contact telephone number:
|
Schedule A
As of 15 July 2015
AstraZeneca PLC
Number of Shares
|
Percent of Outstanding
|
|
The Capital Group Companies, Inc. (“CG”) holdings
|
37,925,813
|
3.001%
|
Holdings by CG Management Companies and Funds:
|
||
Capital Guardian Trust Company
|
5,587,791
|
0.442%
|
Capital International Limited
|
171,800
|
0.014%
|
Capital International Sàrl
|
158,992
|
0.013%
|
Capital International, Inc.
|
72,900
|
0.006%
|
Capital Research and Management Company
|
31,934,330
|
2.527%
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AstraZeneca PLC
Date: 17 July 2015
|
By: /s/ Adrian Kemp
|
Name: Adrian Kemp
|
|
Title: Company Secretary
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Audience Intelligence Company Tunnl Announces Reach & Frequency, Linear TV Measurement Solution
- TinyGemsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Abstract to Be Presented Next Month at ASCO Annual Meeting
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!